Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for men with Hard-to-Treat prostate cancer?

NCT ID NCT07567521

First seen May 06, 2026 · Last updated May 22, 2026 · Updated 3 times

Summary

This study is testing a new drug called TRC003 in 90 men with a type of advanced prostate cancer that has spread and is no longer responding to standard hormone therapy or chemotherapy. The goal is to see if the drug is safe and can shrink tumors or lower PSA levels. Participants will receive up to 6 cycles of treatment in one of three different dose groups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital, Chinese Academy of Medical Sciences, Shanxi Hospital

    Taiyuan, Shanxi, 030013, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fudan University Shanghai Cancer Center

    Shanghai, 200032, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.